9月15日 - ** 维拉治疗公司（VERA.O）股价在盘前交易中上涨11.6%，至38美元
** 该公司表示，其药物Trutakna在一项针对428名免疫球蛋白A肾病（该病可能导致肾衰竭）成年患者的晚期确认性试验中，已达到所有目标
** 据VERA称，该药物在两年内基本稳定了肾功能，并将疾病进展风险较安慰剂组降低了76%
** 在为期两年的研究期间，Trutakna组无患者出现长期透析、肾移植或死亡情况，而安慰剂组有8名患者出现上述情况——VERA
** 安全性与安慰剂组总体相当，未报告新的安全问题
** 该公司计划在该药物于7月获得加速批准后，于2026年第四季度申请美国全面批准
** 截至上一交易日收盘，VERA今年以来累计下跌32.8%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.